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ardioprotective Medication
s Associated With Improved Survival
n Patients With Peripheral Arterial Disease
arm H. H. Feringa, MD,* Virginie H. van Waning, MD,* Jeroen J. Bax, MD, PHD,§
bdou Elhendy, MD, PHD, Eric Boersma, PHD,† Olaf Schouten, MD,‡ Wael Galal, MD,*
adosav V. Vidakovic, MD, Marco J. Tangelder, MD, PHD,‡ Don Poldermans, MD, PHD*
otterdam and Leiden, the Netherlands; and Omaha, Nebraska
OBJECTIVES We sought to investigate the effect of cardiac medication on long-term mortality in patients
with peripheral arterial disease (PAD).
BACKGROUND Peripheral arterial disease is associated with increased cardiovascular morbidity and mortality.
Treatment guidelines recommend aggressive management of risk factors and lifestyle
modifications. However, the potential benefit of cardiac medication in patients with PAD
remains ill defined.
METHODS In this prospective observational cohort study, 2,420 consecutive patients (age, 64 11 years,
72% men) with PAD (ankle-brachial index 0.90) were screened for clinical risk factors and
cardiac medication. Follow-up end point was death from any cause. Propensity scores for
statins, beta-blockers, aspirin, angiotensin-converting enzyme (ACE) inhibitors, calcium
channel blockers, diuretics, nitrates, coumarins, and digoxin were calculated. Cox regression
models were used to analyze the relation between cardiac medication and long-term mortality.
RESULTS Medical history included diabetes mellitus in 436 patients (18%), hypercholesterolemia in 581
(24%), smoking in 837 (35%), hypertension in 1,162 (48%), coronary artery disease in 1,065
(44%), and a history of heart failure in 214 (9%). Mean ankle-brachial index was 0.58
(0.18). During a median follow-up of eight years, 1,067 patients (44%) died. After
adjustment for risk factors and propensity scores, statins (hazard ratio [HR] 0.46, 95%
confidence interval [CI] 0.36 to 0.58), beta-blockers (HR 0.68, 95% CI 0.58 to 0.80), aspirins
(HR 0.72, 95% CI 0.61 to 0.84), and ACE inhibitors (HR 0.80, 95% CI 0.69 to 0.94) were
significantly associated with a reduced risk of long-term mortality.
CONCLUSIONS On the basis of this observational longitudinal study, statins, beta-blockers, aspirins, and
ACE inhibitors are associated with a reduction in long-term mortality in patients with
PAD. (J Am Coll Cardiol 2006;47:1182–7) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.074Cardiology Foundation
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seripheral arterial disease (PAD) is a common manifesta-
ion of systemic atherosclerosis and carries a poor prognosis
s a result of the frequent association with cerebral, renal,
nd coronary artery disease (1–4). Although patients with
AD may present with symptoms ranging from pain on
xertion that is relieved by rest (intermittent claudication) to
ain at rest, ulceration, or gangrene (critical limb ischemia),
ost patients with PAD are asymptomatic (1). The preva-
ence of PAD ranges from 4% in patients aged 40 years and
lder to more than 20% in patients aged 70 years and older
5–10).
Peripheral arterial disease remains an underdiagnosed
isease in the primary care, and patients with PAD are not
From the Departments of *Anesthesiology, †Cardiology, and ‡Vascular Surgery,
rasmus Medical Center, Rotterdam, the Netherlands; §Department of Cardiology,
eiden University Medical Centre, Leiden, the Netherlands; and Internal Medicine,
ection of Cardiology, University of Nebraska, Omaha, Nebraska. Supported by an
nrestricted educational grant from Sanofi-Aventis/BMS.i
Manuscript received July 11, 2005; revised manuscript received September 16,
005, accepted September 19, 2005.reated as aggressively as are patients with other manifesta-
ions of atherosclerotic disease (7,11). The treatment of
AD focuses on walking exercise, aggressive management
f risk factors, lifestyle modifications, and antiplatelet ther-
py (12,13). Cardiovascular events are a major cause of
orbidity and mortality in patients with PAD. However,
he potential benefit of cardiac medication therapy remains
ll defined. Beta-adrenergic receptor blockers were consid-
red relatively contraindicated in PAD; however, several
tudies have revealed that beta-blockers do not adversely
ffect walking capacity, symptoms of intermittent claudica-
ion, and peripheral skin microcirculation (14–16).
In this report, we sought to determine the effect of
hronic treatment with cardiac medication, including
tatins, beta-blockers, aspirins, angiotensin-converting en-
yme (ACE) inhibitors, calcium channel blockers, diuretics,
itrates, coumarins, and digoxin on long-term mortality
mong patients with PAD. In this observational cohort
tudy, we used propensity analysis to adjust for selection bias
n the comparison of treatments.
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ssessment of baseline characteristics. The Erasmus
edical Center serves a population of approximately 3
illion people and acts as a tertiary referral center for
pproximately 30 affiliated hospitals. Patients with sus-
ected or known PAD who were referred to the Erasmus
edical Center, Rotterdam, the Netherlands, between
anuary 1983 and January 2005, for the diagnosis and
anagement of PAD were evaluated. The ankle-brachial
ndex (ABI) at rest was measured in each patient and
atients with PAD (ABI0.90) were included in the study.
On the basis of hospital records and personal interviews
t the time of the visit, a medical history was recorded.
nformation on the presence of previous myocardial infarc-
ion, angina pectoris, previous coronary artery revasculariza-
ion, congestive heart failure, previous stroke or transient
schemic attack, diabetes mellitus, hypertension, current
moking, hypercholesterolemia, and renal dysfunction were
btained. Diabetes mellitus was recorded if patients pre-
ented with a fasting glucose level of 7.0 mmol/l, or in
hose who required treatment. Hypertension was recorded if
atients presented with a blood pressure 140/90 mm Hg
r if patients were medically treated for hypertension.
ypercholesterolemia was recorded when patients pre-
ented with the diagnosis, made by the referring physician,
r if patients were taking lipid-lowering agents. Renal
ysfunction was recorded if patients presented with a serum
reatinine level 2.0 mg/dl (177 mol/l) or in those who
equired dialysis. A baseline 12-lead electrocardiography
as obtained and was considered abnormal in the presence
f one or more of the following: Q waves, ST-segment
epression or elevation, left ventricular hypertrophy, right or
eft bundle branch block, and atrial fibrillation.
se of medication. All prescription and over-the-counter
edications were noted at the time of the visit and were
lassified as follows: statins, beta-blockers, aspirins, ACE
nhibitors, calcium channel blockers (dihydropyridines or
on-dihydropyridines), diuretics, nitrates, coumarins, and
igoxin. To ascertain the long-term use of cardiovascular
edication, medication had to be documented at least at
wo months after the visit.
ollow-up. Patients were followed during a median time
f 8 years (interquartile range, 4 to 11 years) for the
ccurrence of all-cause death. End point was mortality.
nformation about the patient’s vital status was obtained by
pproaching the Office of Civil Registry. For patients who
Abbreviations and Acronyms
ABI  ankle-brachial index
ACE  angiotensin-converting enzyme
CI  confidence interval
HR  hazard ratio
PAD  peripheral arterial diseaseied at our hospital during follow-up, hospital records and Vutopsy results were retrieved and reviewed. For patients
ho died outside our hospital, general practitioners were
pproached to ascertain the cause of death.
tatistical analysis. Continuous data with a normal distri-
ution were expressed as mean and compared using the
tudent t test. Categorical data are presented as percent
requencies, and differences between proportions were com-
ared using the chi-square test with Yates’ correction. The
aplan-Meier method with log-rank test was used to
ompare survival curves in two or more groups. We applied
nivariate and multivariate Cox proportional hazards re-
ression analyses to study the relation between cardiac
edication therapy and long-term survival. Cardiac medi-
ation use was not randomly assigned in these patients, and
he impact of selection bias may profoundly distort the
esults of our study.
Propensity analyses are reliable tools to correct for selec-
ion bias and the rationale for using propensity scores has
een previously described (17). Therefore, separate propen-
ity scores were calculated and ranged from 0.04 to 0.92
or statins, 0.002 to 0.98 for beta-blockers, 0.05 to 0.92 for
spirin, 0.04 to 0.95 for ACE inhibitors, 0.08 to 0.76 for
alcium channel blockers, 0.0001 to 0.87 for diuretics, 0.04
o 0.91 for nitrates, 0.35 to 0.91 for coumarins, and 0.15 to
.77 for digoxin, which were constructed using multiple
ogistic regression analysis. Variables (including baseline
haracteristics as listed in Table 1 and medication use as
isted in Table 2) that were independently associated with
he decision to prescribe statins, beta-blockers, aspirin,
CE inhibitors, calcium channel blockers, diuretics, ni-
able 1. Baseline Characteristics of the 2,420 Study Participants
Characteristic
Total Population
(n  2,420)
emographics
Age (yrs) 64  11
Male gender 1,748 (72%)
ardiovascular history
Angina pectoris 567 (23%)
Previous myocardial infarction 923 (38%)
History of congestive heart failure 214 (9%)
History of cerebrovascular disease 195 (8%)
Previous coronary revascularization 464 (19%)
linical risk factors
Diabetes mellitus 436 (18%)
Hypercholesterolemia 581 (24%)
Hypertension 1,162 (48%)
Current smoking 837 (35%)
Renal failure 127 (5%)
Chronic pulmonary disease 288 (12%)
nkle brachial index 0.70 and 0.90 557 (23%)
nkle brachial index 0.70 1,863 (77%)
lectrocardiography
Q waves 630 (26%)
ST-segment changes 382 (16%)
Left ventricular hypertrophy 113 (5%)
Left bundle branch block 98 (4%)
Right bundle branch block 56 (2%)
Atrial fibrillation 54 (2%)alues are expressed as n (%) or mean  SD.
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Cardiac Medication and Peripheral Arterial Disease March 21, 2006:1182–7rates, coumarins, and digoxin (p  0.25) were included in
he multivariate propensity score. In multivariate analysis,
e adjusted for baseline clinical variables, irrespective of the
ignificance level in univariate analysis. Propensity scores
ere added in separate multivariate models. Hazard ratios
re given with 95% confidence intervals (CIs). For all tests,
p value 0.05 (two-sided) was considered significant. All
nalyses were performed using SPSS-11.0 statistical soft-
are (SPSS Inc., Chicago, Illinois).
ESULTS
aseline characteristics of the 2,420 study participants are
resented in Table 1. The mean age was 64  11 years, and
,748 patients (72%) were men. Severe PAD (ABI 0.70)
as identified in 1,863 patients (77%). The mean ABI was
.58  18. An abnormal electrocardiogram was observed in
,127 patients (47%). Table 2 shows cardiac medication in
he study population. As demonstrated in Figure 1, the
rescription of ACE inhibitors, statins, aspirin, and beta-
lockers increased from 12%, 13%, 15%, and 17%, respec-
ively, in the periods 1983 to 1989 to 30%, 32%, 27%, and
0%, respectively, in the periods 2000 to 2004 (all p 
.001). Propensity analysis demonstrated that patients were
ore likely (p  0.001) to be prescribed statins if they had
ypercholesterolemia, beta-blockers if they had coronary
rtery disease or hypertension, aspirin if they had coronary
rtery disease or a history of cerebrovascular disease, and
CE inhibitors if they had a history of congestive heart
ailure.
During follow-up, death occurred in 1,067 patients
44%). The unadjusted and adjusted associations between
linical variables and long-term mortality are presented in
able 3. In a multivariate model that mutually adjusted for
linical risk factors and propensity scores, statins, beta-
lockers, aspirin, and ACE inhibitors were independently
ssociated with a reduced incidence of long-term mortality
hazard ratio [HR] 0.46, 95% CI 0.36 to 0.58; HR 0.68,
5% CI 0.58 to 0.80; HR 0.72, 95% CI 0.61 to 0.84); and
able 2. Number of Patients (%) Receiving Cardiac Medication
Medications
Total Population
(n  2,420)
tatin 457 (19%)
eta-blockers 602 (25%)
Selective beta-blockers 468 (19%)
Non-selective beta-blockers 134 (6%)
spirin 542 (22%)
CE inhibitors 626 (26%)
alcium channel blockers 677 (28%)
Dihydropyridines 460 (19%)
Non-dihydropyridines 217 (9%)
oumarin 597 (25%)
itrates 568 (23%)
iuretics 365 (15%)
igoxin 159 (7%)
alues are expressed as n (%).
ACE  angiotensin-converting enzyme.R 0.80, 95% CI 0.69 to 0.94, respectively (Table 4).
a
iCalcium channel blockers, diuretics, nitrates, coumarins,
nd digoxin, however, were not significantly and indepen-
ently associated with long-term mortality. In patients
sing beta-blockers, no difference was observed between
elective and non-selective beta-blockers on the long-term
utcome (selective beta-blockers: HR 1.31, 95% CI 0.87
o 1.72).
ISCUSSION
n this cohort study of consecutive patients referred to our
enter for the evaluation of PAD, we found that statins,
eta-blockers, aspirins, and ACE inhibitors were signifi-
igure 1. The prescription of statins, beta-blockers, aspirins, and
ngiotensin-converting enzyme (ACE) inhibitors in patients who were
ncluded in different periods of time.
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ndependent of baseline clinical variables and independent
f PAD severity.
tatins. 5-hydroxy-3-methylglutaryl-coenzyme A reduc-
ase inhibitor drugs (statins) have been shown to reduce
ardiovascular morbidity and mortality in high-risk patients
18–22). The Medical Research Council and the British
eart Foundation (MRC/BHF) Heart Protection Study
andomly allocated 20,536 patients adults with coronary
isease, other occlusive arterial disease, or diabetes to receive
ither simvastatin or placebo and demonstrated in a sub-
roup analysis of 6,748 patients with PAD that statins were
ignificantly associated with a reduction in the rate of major
ascular events (22). The beneficial effect of statins may not
nly be the result of its lipid-lowering effect but may also be
he result of the inhibition of the inflammatory processes of
therosclerosis (23). It has been shown that a reduction in
he inflammatory component through the use of statins
mproved the clinical outcome in patients with coronary
rtery disease, regardless of the reduction in cholesterol
evels (24,25). In patients with PAD, statin use has been
emonstrated to favorably influence leg functioning, walk-
ng performance, ABI values, and symptoms of claudication
26–28). The association of statin use and superior leg
unctioning also was demonstrated in patients with an ABI
Table 3. Univariate and Multivariate Associati
Characteristic
Univariate A
HR and 95%
Age 70 yrs 1.75 (1.55–1
Male gender 1.08 (0.94–1
Coronary artery disease 1.59 (1.41–1
History of heart failure 2.69 (2.26–3
History of cerebrovascular accident 1.55 (1.26–1
Diabetes mellitus 1.42 (1.22–1
Hypercholesterolemia 1.54 (1.29–1
Hypertension 1.22 (1.08–1
Current smoking 1.25 (1.11–1
Renal failure 3.81 (3.09–4
Chronic pulmonary disease 1.52 (1.29–1
Severe PAD (ABI 0.70) 1.40 (1.20–1
Abnormal electrocardiogram 1.71 (1.52–1
ABI  ankle-brachial index; CI  confidence interval; PAD
able 4. Univariate and Multivariate Association Between Cardia
odel Medication
HR and 95% CI
for Overall Death,
Univariate p Value
1 Statin 0.65 (0.54–0.78) 0.001
2 Beta-blocker 0.76 (0.65–0.88) 0.001
3 Aspirin 0.87 (0.77–1.01) 0.08
4 ACE inhibitors 1.13 (0.98–1.30) 0.08
5 Diuretics 1.22 (1.03–1.43) 0.02
6 Ca-antagonists 1.14 (1.01–1.30) 0.04
7 Nitrates 1.36 (1.19–1.56) 0.001
8 Coumarins 1.15 (1.01–1.32) 0.03
9 Digoxin 1.91 (1.57–2.33) 0.001Medication was adjusted for all baseline clinical variables. †Medication was adjusted for a
ACE  angiotensin-converting enzyme, Ca-antagonists  calcium channel blocker; Cf 0.90 to 1.49, which may reflect the favorable influence of
tatins on subclinical PAD (26). A recent study by Schill-
nger et al. (29) showed that statin therapy was associated
ith an improved survival of patients with severe PAD with
levated high-sensitivity C-reactive protein levels (0.42
g/dl). The observation that patients with low inflamma-
ory activity had no survival benefit supports the view that
tatins may exert beneficial effect though anti-inflammatory
roperties.
eta-blockers. Although beta-blockers were considered
elatively contraindicated in patients with PAD, several
tudies showed that beta-blockers do not adversely affect
alking capacity, symptoms of intermittent claudication,
nd peripheral skin microcirculation (14–16). Beta-blockers
re effective antihypertensive agents and improve the prog-
osis of patients with ischemic heart disease and congestive
eart failure and are thus indicated in a majority of patients
ith PAD. However, it seems that beta-blockers have been
nderused by vascular surgeons and primary care providers,
erhaps because of concerns that beta-blockers will aggra-
ate symptoms of intermittent claudication (30,31). Patients
ith PAD are at increased risk for cardiovascular morbidity
nd mortality, and recent studies have demonstrated the
eneficial effect of beta-blockers in these patients. In a study
ohort of 575 patients with symptomatic PAD and with a
f Clinical Variables and Overall Mortality
s Multivariate Analysis
p Value HR and 95% CI p Value
0.001 1.68 (1.48–1.91) 0.001
0.3 1.05 (0.91–1.22) 0.5
0.001 1.39 (1.19–1.62) 0.001
0.001 1.73 (1.42–2.11) 0.001
0.001 1.28 (1.04–1.57) 0.02
0.001 1.35 (1.15–1.60) 0.001
0.001 1.77 (1.44–2.18) 0.001
0.002 1.26 (1.10–1.45) 0.001
0.001 1.27 (1.12–1.44) 0.001
0.001 3.34 (2.68–4.16) 0.001
0.001 1.37 (1.15–1.65) 0.001
0.001 1.21 (1.05–1.41) 0.01
0.001 1.36 (1.17–1.59) 0.001
eripheral arterial disease.
dication and Mortality
R and 95% CI
Overall Death,
Multivariate* p Value
HR and 95% CI
for Overall Death,
Multivariate† p Value
.42 (0.34–0.53) 0.001 0.46 (0.36–0.58) 0.001
.64 (0.55–0.75) 0.001 0.68 (0.58–0.80) 0.001
.78 (0.67–0.91) 0.002 0.72 (0.61–0.84) 0.001
.80 (0.69–0.93) 0.004 0.80 (0.69–0.94) 0.005
.82 (0.68–0.98) 0.03 0.85 (0.71–1.02) 0.09
.04 (0.91–1.19) 0.6 1.03 (0.90–1.18) 0.7
.00 (0.86–1.16) 1.0 1.00 (1.86–1.16) 1.0
.13 (0.98–1.29) 0.08 1.13 (0.98–1.29) 0.08
1.2 (1.01–1.57) 0.04 1.21 (1.95–1.53) 0.1ons o
nalysi
CI
.97)
.24)
.80)
.19)
.90)
.66)
.84)
.38)
.42)
.69)
.80)
.62)
.93)c Me
H
for
0
0
0
0
0
1
1
1ll baseline clinical variables and propensity scores.
I  confidence interval; HR  hazard ratio.
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Cardiac Medication and Peripheral Arterial Disease March 21, 2006:1182–7revious myocardial infarction, Aronow and Ahn (32)
emonstrated that beta-blocker therapy was associated with
53% significant reduction in new coronary events, inde-
endent of other confounding variables (32). This was
onfirmed in a more recently published study demonstrating
three-fold reduction in cumulative cardiac mortality in 78
atients after infarction with intermittent claudication who
ere treated with beta-blocker therapy compared with
atients not treated with beta-blocker therapy (33). It has
een shown that hemodynamic forces (blood pressure and
eart rate) are associated with the development of disrup-
ion of the vulnerable plaque, which consists of an athero-
atous plaque core covered by a thin fibrous cap with
ngoing inflammation (34). Beta-blockers may prevent
laque disruption by reducing heart rate and blood pressure.
n addition, it can be hypothesized that anti-inflammatory
roperties of beta-blockers may limit the phased progression
f cardiovascular disease (35).
spirin. Antiplatelet drugs are now established agents for
reventing cardiovascular and cerebrovascular ischemic
vents. The meta-analysis of the Antithrombotic Trialists’
ollaboration showed a proportional reduction of 23% in
erious vascular events among 9,214 patients with PAD
sing antiplatelet therapy (primarily aspirin), compared with
hose using no antiplatelet therapy (5.8% vs. 7.1%, p 
.004) (36). Limited information is available regarding the
ptimal antiplatelet treatment choice in patients with PAD.
otential adverse effects, including diarrhea, neutropenia,
nd thrombotic thrombocytopenic purpura, may limit the
se of ticlopidine. On the basis of current evidence, aspirin
r clopidogrel seem to be the first-line oral antiplatelet drugs
f choice.
se of ACE inhibitors. The use of ACE inhibitors have
een shown to inhibit the atherosclerotic process and to
mprove peripheral blood pressure and blood flow in pa-
ients with PAD (37). The Heart Outcomes Prevention
valuation (HOPE) study investigators showed that the use
f ramipril significantly reduced the rate of mortality,
yocardial infarction, and stroke in 9,297 high-risk patients
ithout a low ejection fraction or heart failure (38). A recent
andomized placebo-controlled study demonstrated the
eneficial effect of ramipril in patients with clinical or
ubclinical PAD for preventing major cardiovascular events
39). Activation of the renin-angiotensin system seems to be
ssociated with an increased risk of cardiovascular events.
rowing evidence suggest that ACE inhibitors directly
nhibit the atherosclerotic process and improve vascular
ndothelial function (40,41). In addition, the benefit of
CE inhibitors may be independent of the antihypertensive
roperties of these agents (42).
tudy limitations. The results of our study are in accor-
ance with previously published studies demonstrating the
ffect of statins, beta-blockers, aspirin, and ACE inhibitors
or reducing complications in patients with PAD. Several
imitations of our study should be addressed. The major
imitation of this study is that the use of cardiac medicationas not assigned randomly to patients with PAD. However,
roperly conducted observational studies might not produce
isleading or biased results (43). Moreover, we used pro-
ensity analysis and in multivariate analysis we adjusted for
nown possible confounding factors. The strength of using
ropensity score methods lies in its ability to adjust for
election bias because subjects in an observational study have
ot been randomized to exposure groups. A propensity
core generally is defined as the conditional probability of
ssignment to a particular treatment given a vector of
bserved covariates (44). To assess the effect of a treatment
n a situation in which randomization is difficult or impos-
ible, propensity scores are a useful method for matching
embers of different groups. Comparisons of different
roups reveal reliable information on the impact of the
reatment of interest with a small residual bias (17).
onclusions. On the basis of this observational longitudi-
al study, statins, beta-blockers, aspirin, and ACE inhibi-
ors are associated with a reduction in long-term mortality
isk in patients with PAD that is independent of clinical risk
actors and adjusted for propensity scores. The use of cardiac
edications as therapeutic and preventive agents in patients
ith PAD seems to be promising in reducing long-term
ortality and could be incorporated among other management
trategies, including walking exercise and risk factor modifica-
ion. Future studies should be conducted to determine which
atients with PAD would mostly benefit from statins, beta-
lockers, aspirin, and ACE inhibitor therapy.
eprint requests and correspondence: Prof. Don Poldermans,
rasmus Medical Center, University of Rotterdam, Dr. Molewater-
lein 40, 3015 GD Rotterdam, the Netherlands. E-mail:
.poldermans@erasmusmc.nl.
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